Logo
x

Search

Subscribe Now

BMS

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

  • October 4, 2024
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

  • October 4, 2024
BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoriasis

BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoria...

  • September 30, 2024
BMS’ Cobenfy (Xanomeline and Trospium Chloride) Receives the US FDA Approval for Treating Schizophrenia

BMS’ Cobenfy (Xanomeline and Trospium Chloride) Receives the US FDA Approval for Treating Schizophrenia

  • September 27, 2024
PharmaShots Weekly Snapshots (September 02 – September 06, 2024)

PharmaShots Weekly Snapshots (September 02 – September 06, 2024)

  • September 6, 2024
BMS Reports Results from P-III (MAVA-LTE) Trial of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMS Reports Results from P-III (MAVA-LTE) Trial of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

  • September 2, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.